Questions raised most often by clinical leadership, information security teams, regulatory affairs functions and research sponsors during evaluation. Where an answer is incomplete, that is stated rather than avoided.
The platform and the patients
The platform is bounded by physiology. It cannot return a result the body could not produce, because that limit is built into the mathematics rather than applied as a filter afterward. It does not invent. The same record returns the same result every time, which is what allows a finding to be replayed and audited rather than merely described.
What is NeuSymbol?
A private clinical computing environment installed inside the institution that operates it. It reads a patient’s encounters as a connected sequence rather than as separate visits, broadens the differential accordingly, and presents the observations underlying every consideration so that the reasoning can be examined rather than accepted.
Which patients is it built for?
Those who remain unresolved after repeated evaluation. Conditions rare enough that no clinician in the building has encountered one. Presentations spanning several systems, where no single service holds the whole picture. Disease progressing faster than the interval between appointments. And patients receiving a therapy that should be working and is not. They exist in every specialty, they are a small share of any panel, and they account for a disproportionate share of its cost and its unresolved complaints.
Is this specialty-specific software?
No. It is organized around a type of patient rather than a body system. Institutions have applied it in oncology for refractory disease and diverging treatment response, in infectious disease for resistant and atypical presentations, in metabolic and inherited conditions where routine chemistry stays in range while the patient declines, in neurology and psychiatry where rate of change matters more than status at any visit, and in complex multi-system presentations that fall between services.
Does it replace anything currently in place?
No. Existing alerting, order sets and decision support continue unchanged. NeuSymbol addresses the cases those systems are structurally weakest on, and institutions retain everything they are already running.
Clinical workflow
What does a clinician actually see?
A trajectory across the patient’s own prior encounters, with the contributing observations attached, inside the record already in use. No second application, no additional credential, and no new documentation requirement. Every finding carries its rationale: which observations, across which encounters, mapped to which recognized presentation.
Is nursing documentation used?
Yes, and it matters more than most systems allow for. Concerns are frequently charted by nursing staff several encounters before they appear in a physician’s assessment. Free-text observation is read and mapped to standard clinical terminology alongside structured results.
Can a finding be dismissed?
Always, with or without a stated reason. No clinician is blocked, forced or required to justify overriding the system. Dismissals inform local tuning.
Does it interrupt anyone?
No. Findings surface passively when a record is opened rather than as a page, an alarm or a dashboard notification. Sensitivity is agreed with clinical leadership during evaluation rather than shipped as a vendor default.
Data, security and information technology
What data does the platform read?
Structured records, clinical narrative, reported laboratory results, and reported imaging and pathology interpretations. Access is read-only, over the standard health information exchange interfaces the record system already exposes.
How does the platform use imaging and pathology?
It reconciles what was reported against what is in the record. The radiologist and pathologist findings are read alongside laboratory results, encounters, medications and the direction of travel across time. Where a study read as unremarkable sits against the results that followed it, the platform surfaces that divergence with both sources attached, for the clinician to examine and judge. It does not ingest waveform or continuous monitor output.
Does patient data leave the institution?
No, and this follows from where the software runs rather than from a policy that could later be revised. Network communication is outbound only and requires no inbound firewall exception. Where policy requires it, the platform operates with no external connectivity at all, with updates applied through a controlled offline process under institutional change management.
Who holds the encryption keys?
The institution. Reltronic holds no copy and has no means of recovery. This cannot be relaxed by support arrangement.
What happens if the equipment is stolen?
The processing partition is separately powered and remains protected when the unit is disconnected. If tamper sensors register that the enclosure has been opened, the encryption keys are destroyed and resident data becomes mathematically unrecoverable. A stolen appliance is therefore not a breach of institutional patient data.
Does Reltronic hold access to the institutional environment?
No standing access of any kind. There is no always-on tunnel, no vendor account in the institutional directory and no scheduled outbound job. Support access is opened by the institution for a defined purpose, expires automatically, and is logged where institutional staff can read it.
Regulatory status and governance
Is NeuSymbol a medical device?
NeuSymbol advises. The licensed professional decides. It issues no order, takes no autonomous action, and creates no duty that did not already exist. Every finding is presented with the observations beneath it, so it can be examined rather than accepted, and any finding can be dismissed with or without a reason.
How does Reltronic approach regulatory classification?
As an ongoing program rather than a one-time question. Reltronic maintains a standing regulatory function, advised by practitioners who have worked inside the agency, and assesses each platform function separately as capability develops. Where a function requires clearance, Reltronic pursues it. The current written assessment is available to evaluating institutions under non-disclosure.
Is the underlying analysis available for review?
Yes. Reltronic maintains a written, function-by-function classification assessment and provides it to evaluating institutions under non-disclosure. Institutions whose regulatory affairs function wishes to review it before the commercial conversation are encouraged to ask early.
What if an institution’s own analysis reaches a different conclusion?
Reltronic would want to know before deployment rather than after. The assessment is provided precisely so it can be challenged. Where an institution’s view differs, the configuration is adjusted to that view or the deployment does not proceed.
Does this create new liability?
The platform issues no order, takes no autonomous action and creates no duty that did not already exist. Because every finding carries the observations that produced it, a decision to act or not act is documented against visible evidence rather than an unexplained score. No vendor can insulate an institution from clinical liability, and any vendor claiming otherwise should be asked to put it in the contract.
Evaluation
What does an evaluation involve?
Four stages: scoping, installation, silent operation, then written review against the institution’s own patients. Scoping and installation across the first five weeks, with security review beginning at the start rather than the end. Silent operation from weeks six to ten, during which the platform runs against live records without surfacing anything to any clinician. Written review in the final three weeks, examining findings retrospectively against known outcomes in the institution’s own patients.
What does it commit the institution to?
For founding deployments, Reltronic provides the equipment, installation and software licensing across the evaluation period. Commercial terms are discussed directly with the institution rather than published. The written analysis is delivered either way and remains the institution’s property.
Why evaluate against institutional patients rather than published results?
Because published figures from other institutions have limited value in this population. These patients are distributed unevenly, present differently by region and referral pattern, and are too few in any one place for another institution’s numbers to transfer.
What happens at the end?
Where the institution proceeds, findings begin surfacing at thresholds its own clinicians set. Where it does not, the equipment is removed and Reltronic provides written certification that all resident data has been destroyed.
Research, evidence and registries
How is evidence generated without moving data?
The analysis runs inside the institution holding the records. What reaches a sponsor is the evidence rather than the records, which removes the transfer negotiation from the critical path of a study.
Who owns registry data processed by the platform?
The organization that gathered it, without qualification. Reltronic does not take custody, does not retain copies, and has no means of access outside the terms the organization sets and can withdraw.
Is cloud working supported for research?
For exploratory analysis, yes. Evidence intended for regulatory submission is generated on the appliance, because a cloud pipeline cannot produce the attested provenance record a regulator requires. The distinction is stated plainly because it determines which work can support a submission and which cannot.
A question not answered here
Questions that are not covered, or where the answer above is insufficient for a specific governance process, are best raised directly. Briefings are conducted by the people who built the platform and are best attended by clinical leadership, the security team, and whoever is least inclined to believe any of it.